Back to top
more

Incyte (INCY)

(Delayed Data from NSDQ)

$76.13 USD

76.13
2,260,926

+2.01 (2.71%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $75.81 -0.32 (-0.42%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis

The biotech sector was in the news last week as shares of Spectrum surged on positive data from a phase II study while Incyte plunged on the failure of melanoma study.

    NewLink Shares Plunge After Incyte & Merck's Study Fails

    Shares of NewLink Genetics Corp. (NLNT) plunged about 42.6% following the news of the failure of Incyte and Merck's phase III combination study for metastatic melanoma.

      Incyte's Epacadostat Fails in Melanoma Study, Shares Plunge

      Incyte's (INCY) epacadostat in combination with Merck's Keytruda fails to meet primary endpoint of PFS in a phase III melanoma study.

        Incyte (INCY) Up 5.2% Since Earnings Report: Can It Continue?

        Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

          AstraZeneca's Final Data From Key Lung Cancer Study Delayed

          AstraZeneca's (AZN) final overall survival data from the pivotal phase III MYSTIC study on Imfinzi in first line lung cancer to be delayed in the second half of 2018.

            The Zacks Analyst Blog Highlights: Royal Dutch, Mastercard, Itau Unibanco, Suncor and Incyte

            The Zacks Analyst Blog Highlights: Royal Dutch, Mastercard, Itau Unibanco, Suncor and Incyte

              Zacks.com featured highlights include: Incyte, Altice USA, Archrock, Live Nation and PTC

              Zacks.com featured highlights include: Incyte, Altice USA, Archrock, Live Nation and PTC

                Get Rid of 5 Toxic Stocks or Sell Short for Profit

                Overblown toxic stocks are generally susceptible to outside shocks and are loaded with a huge amount of debt.

                  Incyte (INCY) Beats on Q4 Revenues on Strong Jakafi Sales

                  Incyte (INCY) beat on revenues in the fourth quarter driven by an increase in Jakafi sales. The guidance for 2018 was also encouraging.

                    Ekta Bagri headshot

                    Incyte (INCY) Beats on Sales in Q4

                    Incyte (INCY) beat on sales in the fourth quarter driven by growth in Jakafi sales.

                      Why Incyte (INCY) Might Surprise This Earnings Season

                      Incyte (INCY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                        Can Jakafi Performance Drive Incyte's (INCY) Q4 Earnings?

                        Growth in Jakafi sales are likely to help Incyte (INCY) to beat on earnings in Q4.

                          Will Prothena (PRTA) Disappoint Investors in Q4 Earnings?

                          Although Prothena's (PRTA) track record is good, the company is unlikely to beat estimates in the current quarter given the unfavorable rank and Earnings ESP.

                            5 Biotech Stocks Set to Trump Estimates This Earnings Season

                            Total earnings for the medical sector are up 16.9% from the same period last year on 8.5% higher revenues so far.

                              AstraZeneca (AZN) Beats on Q4 Earnings, Guides for 2018

                              AstraZeneca (AZN) beats earnings estimates in fourth quarter on higher product revenues.

                                Lilly (LLY) Beats on Q4 Earnings, Raises 2018 EPS Guidance

                                Lilly (LLY) beats on earnings and sales in Q4 and raises EPS outlook for 2018, reflecting a positive impact of the U.S. tax reform.

                                  Will Amgen (AMGN) Benefit From Growth Drugs in Q4 Earnings?

                                  While Amgen's (AMGN) growth drugs like Prolia & Xgeva might continue to do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.

                                    Merus' Antibody Candidate in Phase II Breast Cancer Study

                                    Merus (MRUS) initiates a phase II study to evaluate its most advanced pipeline candidate in advanced breast cancer.

                                      Lilly (LLY) to Report Q4 Earnings: What's in the Cards?

                                      Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

                                        Zacks.com highlights: Covanta Holding, Altice USA, Incyte and Archrock

                                        Zacks.com highlights: Covanta Holding, Altice USA, Incyte and Archrock

                                          Discard These 4 Toxic Stocks or Sell Short for Profit

                                          Overblown toxic stocks are usually susceptible to outside shocks and loaded with a huge amount of debt.

                                            Celgene to Acquire Impact Biomedicines to Boost Pipeline

                                            Celgene (CELG) announced that it will acquire Impact Biomedicines to bolster its oncology pipeline given the recent series of setbacks.

                                              Zacks.com highlights: Covanta Holding, AMC Entertainment Holdings, Incyte, PTC and Cott

                                              Zacks.com highlights: Covanta Holding, AMC Entertainment Holdings, Incyte, PTC and Cott

                                                Abandon These 5 Toxic Stocks or Sell Short for Profit

                                                Toxic stocks are vulnerable to external shocks and are burdened with high levels of debt.

                                                  AbbVie's RA Candidate Meets Endpoints in 3rd Phase III Study

                                                  AbbVie's (ABBV) RA candidate, upadacitinib, achieves statistically significant improvement in patients in phase III monotherapy study comparing it to methotrexate.